CONJUGATES OF SURROGATE LIGHT CHAIN CONSTRUCTS
The present invention concerns methods for identifying, producing, and engineering binding molecule conjugates, and to the conjugates produced. In particular, the invention concerns Surrobody conjugates composed of an antibody heavy chain variable domain and a surrogate light chain, wherein the surrogate light chain and/or the antibody heavy chain variable domain is conjugated to a therapeutic or diagnostic agent.
1 - 52 . (canceled)
53 . A surrogate light chain construct comprising:
(a) an antibody heavy chain variable sequence comprising three complementarity determining region (CDR) sequences;
(b) a surrogate light chain (SLC) polypeptide comprising a VpreB sequence and a λ5 sequence, wherein the VpreB sequence comprises the amino acid sequence of SEQ ID NO: 54 and the λ5 sequence comprises the amino acid sequence of SEQ ID NO: 55; and
(c) at least one agent linked by a linker to a sulfhydryl functional group present on an amino acid residue at a predetermined position in the SLC polypeptide,
wherein the antibody heavy chain variable sequence and SLC polypeptide associate to form a binding region capable of specifically binding a target antigen.
54 . The surrogate light chain construct of claim 53 , wherein the sulfhydryl functional group has been engineered into the SLC polypeptide by substitution of a cysteine amino acid at the predetermined position.
55 . The surrogate light chain construct of claim 54 , wherein a cysteine residue is substituted at position T16 or T21 of SEQ ID NO: 54 or at position V60, K74, S78, V79, S85, A91, V110, V123, Q131, N133, V166, or V170 of SEQ ID NO: 55.
56 . The surrogate light chain construct of claim 53 , wherein the SLC polypeptide comprises the amino acid sequence of SEQ ID NO: 56, and wherein the sulfhydryl functional group has been engineered into the SLC polypeptide by substitution of a cysteine amino acid at the predetermined position.
57 . The surrogate light chain construct of claim 56 , wherein the cysteine residue is substituted at position T16, T21, V107, K121, S125, V126, S132, A138, V157, V170, Q178, N180, V213, or V217 of SEQ ID NO: 56.
58 . The surrogate light chain construct of claim 53 , wherein the SLC polypeptide comprises the amino acid sequence of SEQ ID NO: 56, and wherein the sulfhydryl functional group is generated by reduction of a native intramolecular or intermolecular disulfide bond of the SLC polypeptide.
59 . The surrogate light chain construct of claim 53 , wherein the SLC polypeptide comprises the amino acid sequence of SEQ ID NO: 56, and wherein the sulfhydryl functional group is generated by reaction of an amino group of a native lysine residue with 2-iminothiolane.
60 . The surrogate light chain construct of claim 53 , wherein the agent is selected from the group consisting of a maytansinoid, a benzodiazepine, a taxoid, CC-1065, a duocarmycin, an enediyne, an auristatin, a tomaymycin derivative, a leptomycin derivative, methotrexate, cisplatin, carboplatin, daunorubicin, doxorubicin, vincristine, vinblastine, melphalan, mitomycin C, chlorambucil, and morpholino doxorubicin.
61 . The surrogate light chain construct of claim 60 , wherein the agent is a maytansinoid.
62 . The surrogate light chain construct of claim 60 , wherein the agent is an auristatin selected from monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF).
63 . The surrogate light chain construct of claim 53 , wherein the linker comprises (i) an amino acid unit comprising a valine-citrulline dipeptide and (ii) a self-immolative spacer unit.
64 . A surrogate light chain construct comprising:
(a) an antibody heavy chain variable sequence comprising three complementarity determining region (CDR) sequences;
(b) a surrogate light chain (SLC) polypeptide, wherein the SLC polypeptide comprises the amino acid sequence of SEQ ID NO: 56; and
(c) at least one agent linked by a linker to a sulfhydryl functional group present on an amino acid residue at a predetermined position in the SLC polypeptide, wherein the linker comprises (i) an amino acid unit comprising a valine-citrulline dipeptide and (ii) a self-immolative spacer unit,
and wherein the antibody heavy chain variable sequence and SLC polypeptide associate to form a binding region capable of specifically binding a target antigen.
65 . The surrogate light chain construct of claim 64 , wherein the sulfhydryl functional group has been engineered into the SLC polypeptide by substitution of a cysteine amino acid at position T16, T21, V107, K121, S125, V126, S132, A138, V157, V170, Q178, N180, V213, or V217 of SEQ ID NO: 56.
66 . The surrogate light chain construct of claim 64 , wherein the sulfhydryl functional group is generated by reduction of a native intramolecular or intermolecular disulfide bond of the SLC polypeptide.
67 . The surrogate light chain construct of claim 64 , wherein the sulfhydryl functional group is generated by reaction of an amino group of a native lysine residue with 2-iminothiolane.
68 . The surrogate light chain construct of claim 64 , wherein the agent is selected from a maytansinoid, a benzodiazepine, a taxoid, a CC-1065 analog, a duocarmycin, an enediyne, an auristatin, a tomaymycin derivative, a leptomycin derivative, methotrexate, cisplatin, carboplatin, daunorubicin, doxorubicin, vincristine, vinblastine, melphalan, mitomycin C, chlorambucil, and morpholino doxorubicin.
69 . The surrogate light chain construct of claim 68 , wherein the agent is a maytansinoid.
70 . The surrogate light chain construct of claim 68 , wherein the agent is an auristatin selected from monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF).
71 . The surrogate light chain construct of claim 68 , wherein the self-immolative spacer unit is p-aminobenzyl alcohol (PAB).